Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
368
resultados
Última actualización
02/11/2026 [10:35:00]
Resultados 25 a 50 de 368
Resumen de: WO2024243362A1
In some aspects, the present disclosure provides a computer-implemented method of predicting efficacies of drugs in a diversity drug set. In general, a computing system receives test results for drugs in a principal drug set for samples of a subject. The computing system trains at least one machine learning model to generate functional predicted results of drugs in the diversity drug set based on the test results for drugs in the principal drug set, and predicts functional predicted results of drugs in the diversity drug set by providing features of the drugs in the diversity drug set as input to the at least one machine learning model.
Resumen de: JP2026171710A
【課題】試料中に含まれる神経系細胞に由来する細胞外小胞を特異的に回収する方法を提供する。【解決手段】試料中に含まれる神経系細胞に由来する細胞外小胞に存在するＡＰＬＰ１を標的として抗ＡＰＬＰ１抗体を用いて免疫沈降を行った後、ペプチドを用いて解離することによって、上記の課題を解決する。【選択図】図１
Resumen de: AU2026210766A1
The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease. ul u l
Resumen de: US20260325651A1
0000 The disclosure relates to lipase modulators, compositions comprising such modulators, and methods of using the same to regulate lipid metabolism, efferocytosis, and/or macrophage function. In certain aspects, the disclosure provides compositions and methods for modulating intracellular lipase activity, lipolysis, inflammatory signaling, membrane remodeling, and/or pro-resolving macrophage polarization, including for treating conditions associated with dysregulated lipid metabolism, impaired efferocytosis, and/or impaired macrophage function. The disclosure also provides in vitro methods for identifying candidate agents that increase macrophage efferocytosis, enhance lipase-associated signaling or activity, increase membrane fluidity, increase receptor clustering or receptor polarization, or promote a pro-resolving macrophage phenotype.
Resumen de: US20260328775A1
0000 Provided is a method of efficiently isolating and detecting an antigen molecule from an antigen-antibody complex in a biological sample. Provided is a method of isolating an antigen molecule from a liquid sample comprising an antigen-antibody complex, the method including: a binding step of binding the antibody molecule in the antigen-antibody complex to an antibody-binding protein by applying the liquid sample to a column on which the antigen-binding protein is immobilized; and an elution step of eluting an elution liquid comprising the antigen molecule by applying a buffer liquid to the column to dissociate the antigen molecule in the antigen-antibody complex from the antibody molecule, wherein the buffer liquid is applied to the column while the pH of the buffer liquid decreases in a continuous or stepwise manner in the elution step.
Resumen de: US20260327309A1
0000 The present disclosure relates to combination therapies comprising immune checkpoint inhibitors and antibodies directed to neurological biomarkers, compositions comprising immune checkpoint inhibitors and antibodies directed to neurological biomarkers, and methods of treatment using such combination therapies and/or compositions.
Resumen de: US20260328785A1
0000 The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods for assessing the severity of and treating severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) or COVID-19. In particular embodiments, a method for treating COVID-19 in a patient comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
Resumen de: US20260328784A1
0000 Alpha-Synuclein mutants and uses thereof are disclosed herein. The mutants of the present invention are non-self-aggregating forms of Alpha-Synuclein which make them a suitable candidate for use as substrates in aggregation assay for evaluating the presence of misfolded α-Syn protein. Also disclosed are kits and method for detection of synucleinopathies in individuals, using the mutants of the present invention.
Resumen de: US20260325476A1
0000 Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.
Resumen de: US20260327196A1
Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.
Resumen de: US20260325565A1
Mammals rely on adaptive immunity to protect against infections and tumors, with the thymus playing a crucial role by producing T cells that target infected or cancerous cells. The thymus, however, undergoes functional decline with age, significantly impairing the immune system in the elderly. To investigate reversing this decline, compositions and methods for activation and differentiation of T cell progenitors in extrathymic tissues are disclosed that stimulate production of differentiated T cells. For example, LNP-mediated delivery of mRNAs encoding DLL-1, IL-7, and FLT3L to the liver is shown to create a temporary site for T cell maturation that enhances T cell-mediated immunity in aged mice without causing autoimmunity. This approach facilitates ectopic T cell development from hematopoietic precursors and activates dendritic cells, providing evidence that engineering adaptive immunity in vivo can effectively mitigate immune aging.
Resumen de: US20260327704A1
This invention provides gene expression profiles useful for diagnosing atrial fibrillation in ischemic stroke and for distinguishing atrial fibrillation in ischemic stroke from arterial (large vessel) stroke or embolic stroke of undetermined source (ESUS).
Resumen de: US20260327296A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: US20260327702A1
0000 The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.
Resumen de: US20260328782A1
0000 The present disclosure provides methods for monitoring inflammation in ALS and other related diseases. Therapeutic interventions based on the results of monitoring methods are also provided.
Resumen de: US20260328758A1
Provided is a method for detecting target substances. The method includes a) introducing a sample containing target substances onto a substrate, b) allowing detection probes conjugated with docking strands to specifically bind to the target substances, c) introducing one or more separate strands capable of complementary binding to the docking strands into the docking strands, either the docking strands or the separate strands, or both, are labeled with at least one donor fluorescent substance and at least one acceptor fluorescent substance, and d) measuring fluorescence signals generated by the FRET between the donor fluorescent substance and the acceptor fluorescent substance to identify the target substances.
Resumen de: US20260328783A1
The present disclosure relates to a biomarker composition for diagnosis of a degenerative brain disease, and more particularly, in an attempt to distinguish between normal people, mild cognitive impairment (MCI) patients, and Alzheimer's disease (AD) patients, provides a biomarker composition that distinguishes between the normal people, mild cognitive impairment (MCI) patients, and Alzheimer's disease (AD) patients by measuring levels of amyloid beta 40 (Aβ40), amyloid beta 42 (Aβ42), brain-derived neurotrophic factor (BDNF), Tau, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), peptidyl-prolyl isomerase (PIN1), collapsing response mediator protein-2 (CRMP2), phospho-Tau231, and olfactory marker protein (OMP) as biomarkers in the blood to identify correlation thereof.
Resumen de: AU2025258452A1
Provided herein are an antibody or antigen binding fragment that specifically recognizes and/or binds to an anti-interleukin 6 receptor. The antibodies or antigen binding fragments provided by the present disclosure have biological activity, FcRn affinity and antibody stability, and have prospects for clinical application.
Resumen de: US20260325655A1
The present disclosure provides compounds of the formulae herein (e.g., Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof, which bind and/or effect degradation of an RNA target. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating or preventing diseases by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, or pharmaceutical compositions thereof.
Resumen de: US20260327295A1
The present invention relates to single-domain antibodies (sdAbs) binding C-reactive protein (CRP). In particular, the invention relates to sdAbs that bind CRP within a specific range of an on-rate constant and off-rate constant. The sdAbs of the present invention can associate and dissociate with CRP in a continuous manner. The invention further relates to nucleic acids encoding anti-CRP sdAbs, methods for detecting CRP, methods of treatment and diagnosis making use of the anti-CRP sdAbs, methods for monitoring CRP levels and apparatuses comprising the anti-CRP sdAbs.
Resumen de: US20260325471A1
Disclosed are methods, systems, compositions, and kits for diagnosing, staging, monitoring, and treating conditions associated with bioenergetic insufficiency in a subject or biological system. The disclosure is grounded in the Unified Theory of Bioenergetic Sufficiency (UTBS), which defines cellular health based on maintaining a Metabolic Sufficiency Ratio (M), the ratio of effective energy generation rate (E) to total energy requirement rate (R), above a critical threshold (M=E/R >M_crit). As well as, Metabolic-Epigenetic-Redox Immune Therapy (MERIT), a new therapeutic class of pharmacological, treat-to-target ketone body therapies for diseases characterized by metabolic, redox, epigenetic, or immune dysregulation.
Resumen de: WO2026221738A1
The present disclosure provides genes and genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy and methods of determining if a subject is responsive or non-responsive to Sigma-1 receptor therapy. The methods can be used to optimize treatment for subjects in need of Sigma-1 receptor therapy. Based on the predicted responsiveness of a subject to the therapy, personalized treatment can be provided to each subject.
Resumen de: WO2026222088A1
The present disclosure describes a method of isolating neuronal-derived extracellular vesicles (NEVs) and obtaining an enriched population of NEVs. The enriched population of NEVs can be used for detecting neurodegenerative diseases. As described herein, ICAM-5 is a specific neuronal marker present on NEVs and offers a highly specific method for NEVs enrichment. Various implementations of the present disclosure provide enhanced sensitivity and accuracy of biomarker detection for neurodegenerative diseases. The high CNS specificity associated with ICAM-5, compared to other reported markers, can significantly improve diagnostic modalities by providing more reliable information that accurately reflects the molecular changes in the brain, leading to earlier and more precise diagnoses.
Resumen de: WO2026222207A1
Disclosed herein are highly sensitive NULISA immunoassays that utilize a capture/release mechanism to reduce non-specific binding and achieve detection with attomolar-level sensitivity to detect multiple forms of phosphorylated brain-derived Tau and total Tau in blood. Kits that can be used for carrying out these highly sensitive immunoassays are also disclosed herein.
Nº publicación: US20260327282A1 22/10/2026
Solicitante:
IMMATICS BIOTECHNOLOGIES GMBH [DE]
Immatics Biotechnologies GmbH
Resumen de: US20260327282A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
BOPI
Sede Electrónica
